In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...
Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.
Positive airway pressure therapy is linked with reduced pulmonary arterial pressures in patients with severe obstructive sleep apnea or obesity hypoventilation syndrome.
WHAT IS PULMONARY ARTERIAL HYPERTENSION (PAH)? Pulmonary Arterial Hypertension (PAH) is a severe and progressive form of pulmonary hypertension, characterised by elevated blood pressure in the ...
Pulmonary thromboendarterectomy is a surgery used to treat chronic thromboembolic pulmonary hypertension. It’s the treatment of choice for this condition. Chronic thromboembolic pulmonary hypertension ...
Early signs of pulmonary hypertension are relatively mild and mimic common conditions such as asthma, poor fitness or anxiety. [Courtesy] Many people are familiar with hypertension, commonly described ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results